Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean BPI Labs, LLC violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

FDA Inspects BPI Labs, LLC: Form 483 with 1 Citations (April 17, 2026)

FDA inspected BPI Labs, LLC in Florida and issued a Form 483 listing 1 inspectional observation following an inspection that concluded 2026-04-17. FDA records classify BPI Labs, LLC as a outsourcing facility. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	BPI Labs, LLC
FEI / inspection ID	3015156709
Inspection end date	April 17, 2026
Citation count	1

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — The written stability program for diug products does not include reliable, meaningful

The written stability program for diug products does not include reliable, meaningful and specific test methods. Sp ecifically, Your fnm failed to establish and follow an adequate written testing program designed to assess impurities profiles for Pyridoxine Hydi·ochloride used in the Tirzepatide and Pyridoxine Hydi·ochloride Injection, as outlined in SOP IQC-002 Stability Program (Revision No. 5, effective 29 M ai·ch 2023). The dmg strengths for Tirzep atide and Pyridoxine Hydrochloride Injection produced and released by your fnm include the following: EMPLOYEE(S) SI GNATURE DATE ISSUED SEE REVERSE Lisa R Hilliard, I nves t iga t or 4/ 1 7/2026 OF THIS PAG E LISaR HalarCI EU6aR. ...nara -s X ~s:~: 04-'7·2026 FORM FDA ~83 (09/ 08) INS PEC TIONAL OB SERVATIONS PAGE 5of? PAGES PREVIOUS EDmON OBSOLEJE

BPI Labs, LLC’s FDA history

Argus HQ has recorded 2 total FDA actions tied to BPI Labs, LLC: 0 warning letters, 0 recalls, 0 approval records, and 2 Form 483 inspection citations.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean BPI Labs, LLC violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for BPI Labs, LLC

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). FDA Inspects BPI Labs, LLC: Form 483 with 1 Citations (April 17, 2026). Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-bpi-labs-llc-2026-04-17-3015156709

MLA

"FDA Inspects BPI Labs, LLC: Form 483 with 1 Citations (April 17, 2026)." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/483/fda-483-bpi-labs-llc-2026-04-17-3015156709.

Chicago

Argus HQ Research. "FDA Inspects BPI Labs, LLC: Form 483 with 1 Citations (April 17, 2026)." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/483/fda-483-bpi-labs-llc-2026-04-17-3015156709.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_bpi_labs_llc_2026_04_17_3015156709_2026,
  title = {FDA Inspects BPI Labs, LLC: Form 483 with 1 Citations (April 17, 2026)},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-bpi-labs-llc-2026-04-17-3015156709},
  note = {Accessed: July 15, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗